No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Cingulate Analyst Ratings
Maxim Group Upgrades Cingulate(CING.US) to Buy Rating, Announces Target Price $8
Express News | Cingulate Inc : Maxim Group Raises to Buy From Hold
10-Q: Q3 2024 Earnings Report
8-K: Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
Cingulate Q3 Net Loss $3.2M
Unlock the Full List